1,118 results on '"Copelan, Edward A."'
Search Results
102. Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission
103. Elevated Ferritin Is Associated with Relapse after Autologous Hematopoietic Stem Cell Transplantation for Lymphoma
104. Hematopoietic Stem Cell Transplantation in Adults with Acute Myeloid Leukemia
105. HLA-Identical Sibling Allogeneic Transplants versus Chemotherapy in Acute Myelogenous Leukemia with t(8;21) in First Complete Remission: Collaborative Study between the German AML Intergroup and CIBMTR
106. Acute Myeloid Leukemia: When to Transplant in First Complete Remission
107. Should busulfan now be part of the standard treatment for patients with acute myeloid leukemia?
108. Cost saving, patient centered algorithm for progenitor cell mobilization for autologous hematopoietic cell transplantation
109. Impact of Letermovir Prophylaxis on Voriconazole Exposure in Allogeneic Hematopoietic Cell Transplant Recipients
110. A Scheme for Defining Cause of Death and Its Application in the T Cell Depletion Trial
111. Hematopoietic Stem Cell Transplantation in Multiple Myeloma
112. High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma
113. Hematopoietic stem-cell transplantation
114. Financial Toxicity Intervention Improves Quality of Life in Hematologic Malignancy Patients
115. Financial Toxicity Intervention Decreases Mortality in High Risk Hematologic Malignancy Patients
116. Impact of Letermovir Prophylaxis on Voriconazole Exposure in Allogeneic Hematopoietic Cell Transplant Recipients
117. Characteristics Affecting Durability and Tolerability of Imatinib in Patients Switched from Brand to Generic and Newly Diagnosed Patients Initially Prescribed Generic Imatinib for Chronic Myeloid Leukemia
118. Specialty Pharmacy and Physician Partnership Optimizes Clinical Pathway Adherence in Myelofibrosis (MF): Initial Analysis of a Quality Improvement Initiative
119. 553. Critically Ill patients Receiving Tocilizumab Compared With Those Not Receiving Tocilizumab for Treatment of COVID-19
120. Hematopoietic Growth Factors in the Supportive Care and Treatment of Patients with Hematologic Neoplasms
121. Expression of phosphorylated signal transducer and activator of transcription 5 is associated with an increased risk of death in acute myeloid leukemia
122. Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia
123. Hematopoietic Stem Cell Transplantation in Philadelphia-Positive Acute Lymphoblastic Leukemia
124. Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation
125. A Comparison of Cyclophosphamide and Total Body Irradiation with Etoposide and Total Body Irradiation as Conditioning Regimens for Patients Undergoing Sibling Allografting for Acute Lymphoblastic Leukemia in First or Second Complete Remission
126. High Disease Burden Is Associated with Poor Outcomes for Patients with Acute Myeloid Leukemia Not in Remission Who Undergo Unrelated Donor Cell Transplantation
127. Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres
128. The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls
129. Multiple unit umbilical cord blood transplantation with total body irradiation, etoposide and antithymocyte globulin for adult haematological malignancy patients
130. Predicting Hematopoietic Stem Cell Mobilization Failure in Patients With Multiple Myeloma: A Simple Method Using Day 1 Cd34+ Cell Yield
131. Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma
132. Abstract 1920: Response to hypomethylating agents based on cytidine deaminase expression, genetic polymorphisms, and NPM1 mutation status in acute myeloid leukemia
133. Improving the Odds
134. Levine Cancer Institute Approach to Pandemic Care of Patients With Cancer
135. Outcomes in minority patients (pt) with aggressive B cell lymphoma (BCL) if optimally managed with equal access to care and nurse navigation (NN).
136. Incidence, Risk Factors for and Outcomes of Transplant‐Associated Thrombotic Microangiopathy
137. Favorable Survival Outcomes in Acute Myeloid Leukemia (AML) Patients (pts) Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) without Achieving Complete Remission (CR) to Non-Intensive Chemotherapy
138. Impact of Weekend Admissions on Quality of Care and Outcomes in Patients With Acute Myeloid Leukemia
139. Navigating the nexus of MRD and novel agents in ALL
140. Patient Reported Financial Toxicity in Myeloproliferative Neoplasms
141. Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor
142. Minorities Do Not Have Worse Outcomes for Diffuse Large B Cell Lymphoma (DLBCL) If Optimally Managed
143. Evaluation ofCYP2C19 Genotype‐Guided Voriconazole Prophylaxis After Allogeneic Hematopoietic Cell Transplant
144. Incidence and reasons for late failure after allogeneic haematopoietic cell transplantation following BuCy2 in acute myeloid leukaemia
145. Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide
146. Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation
147. Thalidomide-Induced Fulminant Hepatic Failure
148. Medical Progress: Hematopoietic Stem-Cell Transplantation
149. Unrelated Donor Marrow Transplantation for B-Cell Chronic Lymphocytic Leukemia After Using Myeloablative Conditioning: Results From the Center for International Blood and Marrow Transplant Research
150. Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.